Karens case is rare but exhibits how the unexpected side effects of these drugs arent always as nice as the ones weve outlined above
Knerr PJ, Mowery SA, Douros JD, Premdjee B, Hjollund KR, He Y, et al
Supporting your bodys natural GLP-1 production is simply one piece of a much larger picture
For example, a study of over 2,000 patients on semaglutide-based programs showed the following: Participants who tapered their dose over approximately nine weeks lost an average of 2.1% additional weight during the tapering period
[DOI] [PMC free article] [PubMed] [Google Scholar] [126].Saunders WB, Nguyen H, Kalsekar I, Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study, Diabetes, metabolic syndrome and obesity : targets and therapy, 9 (2016) 217223